K Borchert

874 total citations
20 papers, 542 citations indexed

About

K Borchert is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Oncology. According to data from OpenAlex, K Borchert has authored 20 papers receiving a total of 542 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Pulmonary and Respiratory Medicine, 7 papers in Surgery and 6 papers in Oncology. Recurrent topics in K Borchert's work include Esophageal Cancer Research and Treatment (4 papers), Gastric Cancer Management and Outcomes (4 papers) and Clinical Nutrition and Gastroenterology (3 papers). K Borchert is often cited by papers focused on Esophageal Cancer Research and Treatment (4 papers), Gastric Cancer Management and Outcomes (4 papers) and Clinical Nutrition and Gastroenterology (3 papers). K Borchert collaborates with scholars based in Germany, Austria and Israel. K Borchert's co-authors include Johann Ockenga, Michael P. Manns, Stephan C. Bischoff, Herbert Lochs, E. Stüber, Oliver A. Cornely, Claudia Beisel, Raoul Herbrecht, Werner Heinz and Gerda Silling and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

K Borchert

19 papers receiving 522 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
K Borchert Germany 10 174 169 166 158 155 20 542
M. Koulentaki Greece 16 87 0.5× 34 0.2× 151 0.9× 374 2.4× 63 0.4× 43 671
Mircea Mănuc Romania 12 52 0.3× 69 0.4× 110 0.7× 170 1.1× 46 0.3× 53 443
Daniel E. Polter United States 13 174 1.0× 168 1.0× 362 2.2× 131 0.8× 21 0.1× 18 660
J C Delchier France 16 117 0.7× 166 1.0× 454 2.7× 161 1.0× 39 0.3× 26 756
Puo‐Hsien Le Taiwan 12 134 0.8× 155 0.9× 145 0.9× 125 0.8× 50 0.3× 78 454
Seok Ho Dong South Korea 14 76 0.4× 131 0.8× 231 1.4× 111 0.7× 28 0.2× 65 470
Christian Scheurlen Germany 14 76 0.4× 195 1.2× 422 2.5× 165 1.0× 21 0.1× 26 729
S Vavricka Switzerland 12 82 0.5× 61 0.4× 275 1.7× 153 1.0× 60 0.4× 27 649
Jung Won Jeon South Korea 14 155 0.9× 142 0.8× 153 0.9× 50 0.3× 18 0.1× 48 444
M L Szeto China 12 84 0.5× 140 0.8× 253 1.5× 158 1.0× 27 0.2× 22 608

Countries citing papers authored by K Borchert

Since Specialization
Citations

This map shows the geographic impact of K Borchert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K Borchert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K Borchert more than expected).

Fields of papers citing papers by K Borchert

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K Borchert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K Borchert. The network helps show where K Borchert may publish in the future.

Co-authorship network of co-authors of K Borchert

This figure shows the co-authorship network connecting the top 25 collaborators of K Borchert. A scholar is included among the top collaborators of K Borchert based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K Borchert. K Borchert is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Hofheinz, Ralf‐Dieter, Georg Martin Haag, Thomas J. Ettrich, et al.. (2020). Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2-positive resectable esophagogastric adenocarcinoma: Final results of the PETRARCA multicenter randomized phase II trial of the AIO.. Journal of Clinical Oncology. 38(15_suppl). 4502–4502. 60 indexed citations
4.
Stein, Jürgen M., et al.. (2018). Oral versus intravenous iron therapy in patients with inflammatory bowel disease and iron deficiency with and without anemia in Germany – a real-world evidence analysis. SHILAP Revista de lepidopterología. 1 indexed citations
5.
Moehler, Markus, Peter Thuss‐Patience, Baruch Brenner, et al.. (2017). Cisplatin/5-FU (CF) +/- panitumumab (P) for patients (pts) with non-resectable, advanced, or metastatic esophageal squamous cell cancer (ESCC): An open-label, randomized AIO/TTD/BDGO/EORTC phase III trial (POWER).. Journal of Clinical Oncology. 35(15_suppl). 4011–4011. 8 indexed citations
6.
Hofheinz, Ralf‐Dieter, K Borchert, Albrecht Kretzschmar, et al.. (2017). Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2 positive resectable esophagogastric adenocarcinoma: Petrarca—A phase II trial of the German AIO.. Journal of Clinical Oncology. 35(15_suppl). TPS4133–TPS4133. 9 indexed citations
7.
8.
Gandhi, Maher K., Jamie P. Nourse, Colm Keane, et al.. (2014). A Comprehensive Analysis of the Cellular and EBV-Specific MicroRNAome in Primary CNS PTLD Identifies Different Patterns Among EBV-Associated Tumors. American Journal of Transplantation. 14(11). 2577–2587. 42 indexed citations
9.
Schmitt, Michael, Rudolf Trenschel, Herbert G. Sayer, et al.. (2014). Conditioning with treosulfan and fludarabine for patients with refractory or relapsed non-Hodgkin lymphoma. Molecular and Clinical Oncology. 2(5). 773–782. 5 indexed citations
10.
Schmitt, Michael, Xiangdong Xu, Inken Hilgendorf, et al.. (2013). Mobilization of PBSC for allogeneic transplantation by the use of the G-CSF biosimilar XM02 in healthy donors. Bone Marrow Transplantation. 48(7). 922–925. 24 indexed citations
11.
Schmitt, Michael, Xun Xu, K Borchert, et al.. (2011). Use of the G-CSF Biosimilar Ratiograstim® to Mobilize Peripheral Stem Cells in Healthy Donors for Allogeneic Stem Cell Transplantation. Blood. 118(21). 1928–1928. 2 indexed citations
12.
Patejdl, Robert, K Borchert, Reiner Benecke, et al.. (2011). Posterior reversible encephalopathy syndrome (PRES): An unusual primary manifestation of a diffuse large B-cell lymphoma. Clinical Neurology and Neurosurgery. 113(9). 819–821. 10 indexed citations
13.
Casalegno‐Garduño, Rosaely, Claudia Meier, Jiju Mani, et al.. (2011). Expression of RHAMM and WT1 As Well As T Cell Responses to These Antigens Before and After Allogeneic Stem Cell Transplantation in Patients with Leukemia. Blood. 118(21). 4315–4315. 1 indexed citations
14.
Rüping, Maria J. G. T., Werner Heinz, Volker Rickerts, et al.. (2009). Forty-one recent cases of invasive zygomycosis from a global clinical registry. Journal of Antimicrobial Chemotherapy. 65(2). 296–302. 142 indexed citations
15.
Heinz, Werner, Anupma Jyoti Kindo, Volker Rickerts, et al.. (2009). Forty-One Recent Cases of Invasive Zygomycosis From a Global Clinical Registry.. Blood. 114(22). 4736–4736. 6 indexed citations
16.
Ockenga, Johann, K Borchert, E. Stüber, et al.. (2005). Glutamine-enriched total parenteral nutrition in patients with inflammatory bowel disease. European Journal of Clinical Nutrition. 59(11). 1302–1309. 62 indexed citations
17.
Ockenga, Johann, et al.. (2002). Effect of glutamine-enriched total parenteral nutrition in patients with acute pancreatitis. Clinical Nutrition. 21(5). 409–416. 86 indexed citations
18.
Ockenga, Johann, et al.. (2000). A randomised, controlled trial of glutamine supplementation in gastroenterological patients scheduled for parenteral nutrition. Gastroenterology. 118(4). A775–A775. 1 indexed citations
19.
Borchert, K, et al.. (1971). [Problems of postanesthetic vomiting following eye operations].. PubMed. 158(3). 450–5. 1 indexed citations
20.
Borchert, K. (1968). [Contribution on the problem of postoperative pulmonary complications].. PubMed. 93(45). 1561–9.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by M. Koulentaki Breakdown of academic impact, for papers by Mircea Mănuc Breakdown of academic impact, for papers by Daniel E. Polter Breakdown of academic impact, for papers by J C Delchier Breakdown of academic impact, for papers by Puo‐Hsien Le Breakdown of academic impact, for papers by Seok Ho Dong Breakdown of academic impact, for papers by Christian Scheurlen Breakdown of academic impact, for papers by S Vavricka Breakdown of academic impact, for papers by Jung Won Jeon Breakdown of academic impact, for papers by M L Szeto
Rankless by CCL
2026